坦德姆糖尿病护理公司的份额随着收入增加31.4%而上升,尽管分析师的评级不一。 Tandem Diabetes Care's shares rose as revenue increased 31.4%, despite mixed analyst ratings.

坦德姆糖尿病护理(NASDAQ:TNDM)看到机构持有量的变化和股价的差距。 Tandem Diabetes Care (NASDAQ: TNDM) saw changes in institutional holdings and a gap-up in share price. Cinctive Capital 和 Jacobs Levy 减持了他们的股份，而其他人则增加了他们的股份。 Cinctive Capital and Jacobs Levy reduced their stakes, while others increased theirs. Tandem报告说,收入增长31.4%,收入估计数比收入估计数高。 Tandem reported a 31.4% revenue increase and beat earnings estimates. 分析家给出的评级有好有坏,但一般是肯定的目标,加拿大皇家银行设定的最高值为65.00美元。 Analysts gave mixed ratings but generally positive targets, with Royal Bank of Canada setting the highest at $65.00. 该公司侧重于糖尿病技术,包括T:slim X2胰岛素系统。 The company focuses on diabetes technology, including the t:slim X2 insulin system.